Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 71 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2014', provides an overview of the Pancreatic Ductal Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pancreatic Ductal Adenocarcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pancreatic Ductal Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pancreatic Ductal Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pancreatic Ductal Adenocarcinoma Overview 7
Therapeutics Development 8
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview 8
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis 9
Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies 10
Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 11
Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Pancreatic Ductal Adenocarcinoma - Products under Development by Companies 14
Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes 15
Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development 16
centrose llc 16
FibroGen, Inc. 17
Gilead Sciences, Inc. 18
Incuron, LLC 19
Incyte Corporation 20
Medisyn Technologies, Inc. 21
Merck & Co., Inc. 22
OncoEthix SA 23
Pfizer Inc. 24
SillaJen Co. Ltd. 25
Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
CBL-0137 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
EDC-1 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
FG-3019 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Hu-5F9 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
INCB-39110 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
JX-929 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
momelotinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MRK-003 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MT-477 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
OTX-015 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PF-03084014 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Pancreatic Ductal Adenocarcinoma - Recent Pipeline Updates 55
Pancreatic Ductal Adenocarcinoma - Dormant Projects 67
Pancreatic Ductal Adenocarcinoma - Discontinued Products 68
Pancreatic Ductal Adenocarcinoma - Product Development Milestones 69
Featured News & Press Releases 69
Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

List of Tables
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2014 8
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Pancreatic Ductal Adenocarcinoma - Pipeline by centrose llc, H2 2014 16
Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H2 2014 17
Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H2 2014 18
Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H2 2014 19
Pancreatic Ductal Adenocarcinoma - Pipeline by Incyte Corporation, H2 2014 20
Pancreatic Ductal Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H2 2014 21
Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H2 2014 22
Pancreatic Ductal Adenocarcinoma - Pipeline by OncoEthix SA, H2 2014 23
Pancreatic Ductal Adenocarcinoma - Pipeline by Pfizer Inc., H2 2014 24
Pancreatic Ductal Adenocarcinoma - Pipeline by SillaJen Co. Ltd., H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Pancreatic Ductal Adenocarcinoma Therapeutics - Recent Pipeline Updates, H2 2014 55
Pancreatic Ductal Adenocarcinoma - Dormant Projects, H2 2014 67
Pancreatic Ductal Adenocarcinoma - Discontinued Products, H2 2014 68